

Helsel Dave  
 Form 3  
 February 01, 2019

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|   |         |                                      |  |  |
|---|---------|--------------------------------------|--|--|
| 1. Name and Address of Reporting Person * |         | 2. Date of Event Requiring Statement | 3. Issuer Name <b>and</b> Ticker or Trading Symbol   |  |
| Â Helsel Dave                             |         | (Month/Day/Year)                     | ANGIODYNAMICS INC [ANGO]   |  |
| (Last)                                    | (First) | (Middle)                             | 4. Relationship of Reporting Person(s) to Issuer   | 5. If Amendment, Date Original Filed(Month/Day/Year) |
|   |         | 01/23/2019                           |  |  |
| 14 PLAZA DRIVE                            |         |                                      | (Check all applicable)   |  |
| (Street)                                  |         |                                      | <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other<br>(give title below)    (specify below)<br>SVP Global Operations and R&D |  |
| LATHAM,Â NYÂ 12110                        |         |                                      | 6. Individual or Joint/Group Filing(Check Applicable Line)   |  |
| (City)                                    | (State) | (Zip)                                | <input checked="" type="checkbox"/> Form filed by One Reporting Person<br><input type="checkbox"/> Form filed by More than One Reporting Person  |  |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock                    | 14,090 <sup>(1)</sup>                                 | D  | Â   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---|--|--|---|
|  | Date Exercisable    Expiration Date                      | Title    Amount or Number of  |  |  |   |

Edgar Filing: Helsel Dave - Form 3

|   |       |            |              | Shares |          | (I)<br>(Instr. 5) |   |
|---|-------|------------|--------------|--------|----------|-------------------|---|
| Non-Qualified Stock Option (right to buy) | Â (2) | 12/18/2027 | Common Stock | 50,000 | \$ 17.2  | D                 | Â |
| Non-Qualified Stock Option (right to buy) | Â (3) | 07/18/2028 | Common Stock | 15,663 | \$ 20.93 | D                 | Â |
| Performance Right                         | Â (4) | Â (4)      | Common Stock | 10,000 | \$ 0     | D                 | Â |
| Performance Right                         | Â (5) | Â (5)      | Common Stock | 9,834  | \$ 0     | D                 | Â |

## Reporting Owners

| Reporting Owner Name / Address                    | Relationships |           |                                 |       |
|---|---------------|-----------|---------------------------------|-------|
|   | Director      | 10% Owner | Officer                         | Other |
| Helsel Dave<br>14 PLAZA DRIVE<br>LATHAM, NY 12110 | Â             | Â         | Â SVP Global Operations and R&D | Â     |

## Signatures

/s/ Stephen A. Trowbridge, Attorney  
in Fact

02/01/2019

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) This number includes (i) 7,500 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") underlying restricted stock units, of which 2,500 shares will vest on each of December 18, 2019, 2020 and 2021, and (ii) 4,916 shares of Common Stock of the Company underlying restricted stock units, of which 1,228 shares will vest on each of July 18, 2019 and 2020, and 1,230 shares will vest on each of July 18, 2021 and 2022.

(2) These stock options vest in four annual installments beginning on December 18, 2018, such that 12,500 options vested on December 18, 2018, and 12,500 options will vest on each of December 18, 2019, 2020 and 2021.

(3) These stock options vest in four annual installments beginning on July 18, 2019, such that 3,916 options will vest on each of July 18, 2019, 2020 and 2021, and 3,915 options will vest on July 18, 2022.

(4) Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

(5) Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

Â

### Remarks:

Exhibit List: Â Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

## Edgar Filing: Hesel Dave - Form 3

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.